"10.1371_journal.pone.0141669","plos one","2015-10-28T00:00:00Z","Wibke Deisting; Tobias Raum; Peter Kufer; Patrick A Baeuerle; Markus Münz","Amgen Research (Munich) GmbH, Munich, Germany; MPM Capital, Cambridge, Massachusetts, United States of America","Conceived and designed the experiments: TR MM WD. Performed the experiments: WD. Analyzed the data: TR MM WD PK. Contributed reagents/materials/analysis tools: PK. Wrote the paper: MM WD PAB.","Funding of this study has been supplied by AMGEN Inc., the employer of Wibke Deisting, Tobias Raum, Peter Kufer and Markus Münz and the former employer of Patrick A. Baeuerle who is now employed by MPM Capital. All authors have equity positions in the company. AMGEN is focused on the development of BiTE antibodies for the treatment of malignant diseases. AMGEN is the maker of AMG 110. Besides AMG 110 that was used for this study the BiTE platform holds other BiTE molecules in the pipeline and has one product marketed named BLINCYTO. The authors Tobias Raum, Peter Kufer, Markus Münz and Patrick A. Baeuerle hold various patents relevant for the BiTE platform, including a patent for AMG 110. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","10","Wibke Deisting","WD",5,TRUE,3,1,4,3,TRUE,TRUE,FALSE,0,NA,FALSE
